FDA May Approve Another Alzheimer’s Drug

In phase three of it's clinical trial, results revealed delay in the disease's progression.

A second drug aimed to treat Alzheimer’s may be on the market by the end of this year.

Earlier this month, the FDA gave its full approval for Leqembi which marked a historic shift in the treatment of Alzheimer’s. For the first time, doctors have a medicine to prescribe that has been proven to slow the loss of memory and ability to do daily tasks that come with the disease.

Now, Eli Lilly’s ‘donanemab’ may join Leqembi. In phase three of it’s clinical trial, results revealed delay in the disease’s progression. Based on the positive results, Lilly completed its FDA submission for the drug, and expects regulatory action by the end of this year.

Both Leqembi and donanemab work by clearing buildups of a protein in the brain called amyloid, a main cause of Alzheimer’s.